.jpg)
BMS shrugs off Cobenfy's schizophrenia hit as it gears up for Alzheimer's psychosis readout, 7 trial starts
Bristol Myers Squibb remains confident that Cobenfy can come out ahead of its recent clinical defeat, and it's planning to start a group of “difficult studies” this year in three indications.
Bristol Myers Squibb remains confident that Cobenfy can come out ahead of its recent clinical defeat, and it's planning to start a group of “difficult studies” this year in three indications.
